The integral membrane protein SMIM4 modulates redox balance via malate compartmentalization in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a nutrient-poor tumor microenvironment that forces cancer cells to undergo metabolic reprogramming to survive. While the importance of mitochondrial metabolism in this context is increasingly recognized, the regulatory mechanisms governing NADPH generation—a critical reducing agent for antioxidant defense—remain poorly understood. This study investigates the role of the poorly characterized mitochondrial protein SMIM4 in PDAC metabolic regulation and patient prognosis.

Using transcriptome analysis of PDAC patient cohorts, the researchers identified SMIM4 as a favorable prognostic marker. They employed CRISPR/Cas9-mediated knockout, shRNA-mediated depletion, and rescue experiments in human PDAC cell lines (MIA PaCa-2 and PANC-1) to assess the impact of SMIM4 on cell proliferation, mitochondrial respiration, and survival under nutrient-deficient conditions. Mechanistic studies included co-immunoprecipitation, mass spectrometry, and metabolic flux analysis to determine how SMIM4 interacts with mitochondrial transporters to influence redox balance.

SMIM4 functions as an assembly factor for SLC25A1-containing complexes, which are responsible for the mitochondrial malate/citrate exchange. When SMIM4 is depleted, the assembly of these complexes is impaired, leading to a redistribution of malate from the mitochondria to the cytosol. This cytosolic accumulation of malate promotes NADPH generation through the activity of malic enzymes, thereby enhancing the cell's antioxidant capacity. Consequently, SMIM4-depleted PDAC cells exhibit increased resistance to glucose deprivation and ferroptosis-inducing agents like RSL3 and IKE. Conversely, high SMIM4 expression correlates with better patient survival and increased sensitivity to ferroptosis-inducing therapies.